Clinical Trial Update: Front-line Therapy With Carfilzomib, Lenalidomide, and Dexamethasone Induction [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating frontline induction with carfilzomib, lenalidomide, and dexamethasone in multiple myeloma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Kyprolis (carfilzomib)
• Revlimid (lenalidomide)

Snippet

Sponsor: University Hospital, Toulouse | Conditions: Multiple Myeloma | Phase 2 | Status: COMPLETED